A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung.
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase of the ERBB2 family that has important roles in the proliferation and metastasis of tumor cells. It is frequently overexpressed in common solid tumors and has become a favored target for orally administered small-molecule tyrosine kinase inhibitors (TKI) and monoclonal antibody-based therapy. Gain-of-function somatic mutations of the EGFR tyrosine kinase domain have been associated with the response of some patients with non-small-cell lung carcinoma to TKIs. We evaluated three methods of EGFR mutation analysis to identify an optimal assay for clinical testing based on comparison of diagnostic sensitivity, technical difficulty, and cost (Tab. 1, Fig. 1, Ref. 12).